Login
Existing Account

Please login first to complete purchase/ quotation request, view custom order reports, or create favorites list.

Customer ID:
Password:
Stay Logged In


Forgot your Customer ID or Password?
New Account

Don't have an account with us yet? Please set up an account to place order or obtain customer services.

Recombinant Proteins  >  α-Synuclein & β-Synuclein  >>  Recombinant human α-Synuclein (1-140), biotin labeled  

Product Name Recombinant human α - Synuclein (1 - 140), biotin labeled  
Size 200 ľg
Catalog # AS-55581
US$ $462
Purity Greater than 90% as determined by SDS-PAGE and mass spectrometry.
Description

The recombinant human α-synuclein (1-140) (GenBank Accession # NP_000336) was expressed and purified from E. coli and conjugated with biotin. Recombinant protein is produced without an affinity tag.

Parkinson's disease is predominantly a movement disorder resulting from degeneration of dopaminergic neurons in the substantia nigra. The cause of the disease is unknown, but substantial evidence suggests that the aggregation of α-synuclein is a critical step in the etiology of Parkinson's disease (PD). α-Synuclein is an abundant brain protein of 140 residues that is present in high concentrations at presynaptic terminals and is found in both soluble and membrane-associated fractions of the brain. Several possible functions have been suggested, and it appears to be involved in vesicle release and trafficking. In vitro incubation of α-synuclein in the presence of certain amounts of salt (i.e. 0.1M NaCl) with agitation can form fibril structure.

Related Products:
EndoClearTM Recombinant Human alpha-Synuclein Protein

SensoLyteŽAnti-alpha-Synuclein (Human, Mouse, Rat) ELISA Kit

Parkinson's & Alzheimer's Disease Products

Detailed Information Datasheet
Material Safety Data Sheets (MSDS)
Storage Biotinylated human α -synuclein is supplied frozen at 1 mg/ml in 10 mM sodium phosphate buffer (pH=7.4). Store at 2-4 şC for immediate use within 1 week or at -80 şC for up to 12 months. Keep in dark and avoid repeated freeze-thaw cycles.
References 1. Trojanowski, J. Q. & Lee, V. M. (2003) Ann. N. Y. Acad. Sci. 991, 107-110.
2. Masliah, E., et al. (2000) Science 287, 1265-1269.
3. Van Der, P. H, et al. (2000) J. Neurosci. 20, 6021-6029.
4. Feany, M. B. & Bender, W. W. (2000) Nature 404, 394-398.
5. Weinreb, P. H., et al. (1996) Biochemistry 35, 13709-13715
     
  < Back